Venetoclax - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for venetoclax and what is the scope of freedom to operate?
Venetoclax
is the generic ingredient in one branded drug marketed by Abbvie and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.Venetoclax has two hundred and fifty-nine patent family members in forty-three countries.
One supplier is listed for this compound.
Summary for venetoclax
International Patents: | 259 |
US Patents: | 10 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 99 |
Clinical Trials: | 473 |
Patent Applications: | 3,123 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for venetoclax |
What excipients (inactive ingredients) are in venetoclax? | venetoclax excipients list |
DailyMed Link: | venetoclax at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for venetoclax
Generic Entry Date for venetoclax*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for venetoclax
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Benjamin Tomlinson | Phase 1/Phase 2 |
Antonio M Jimenez Jimenez | Phase 1 |
Flamingo Therapeutics NV | Phase 1 |
Pharmacology for venetoclax
Drug Class | BCL-2 Inhibitor |
Mechanism of Action | P-Glycoprotein Inhibitors |
Physiological Effect | Increased Cellular Death |
Anatomical Therapeutic Chemical (ATC) Classes for venetoclax
Paragraph IV (Patent) Challenges for VENETOCLAX
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
VENCLEXTA | Tablets | venetoclax | 10 mg, 50 mg and 100 mg | 208573 | 2 | 2020-04-13 |
US Patents and Regulatory Information for venetoclax
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-001 | Apr 11, 2016 | RX | Yes | No | 11,590,128 | ⤷ Subscribe | ⤷ Subscribe | ||||
Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-001 | Apr 11, 2016 | RX | Yes | No | 10,730,873 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-002 | Apr 11, 2016 | RX | Yes | No | 9,174,982 | ⤷ Subscribe | ⤷ Subscribe | ||||
Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-002 | Apr 11, 2016 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-001 | Apr 11, 2016 | RX | Yes | No | 8,722,657 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-002 | Apr 11, 2016 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-002 | Apr 11, 2016 | RX | Yes | No | 8,722,657 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for venetoclax
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
AbbVie Deutschland GmbH Co. KG | Venclyxto | venetoclax | EMEA/H/C/004106 Venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).Venclyxto in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.Venclyxto monotherapy is indicated for the treatment of CLL:- in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B cell receptor pathway inhibitor, or- in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.Venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. |
Authorised | no | no | no | 2016-12-04 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for venetoclax
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Uruguay | 33047 | AGENTES INDUCTORES DE APOPTOSIS PARA EL TRATAMIENTO DEL CÁNCER Y DE ENFERMEDADES INMUNES Y AUTOINMUNES | ⤷ Subscribe |
Canada | 2813985 | DISPERSIONS SOLIDES EXTRUDEES EN FUSION CONTENANT UN AGENT INDUISANT L'APOPTOSE (MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT) | ⤷ Subscribe |
Costa Rica | 20180289 | DISPERSIONES SÓLIDAS EXTRUIDAS POR FUSIÓN QUE CONTIENEN UN AGENTE INDUCTOR DE APOPTOSIS (Divisional 2013-0224) | ⤷ Subscribe |
New Zealand | 595708 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ⤷ Subscribe |
Singapore | 189477 | MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ⤷ Subscribe |
South Africa | 201108616 | APOPTOSIS-INDUCING AGENTS FOR THE TRATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ⤷ Subscribe |
Japan | 6038195 | ⤷ Subscribe | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for venetoclax
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2435432 | 1790021-8 | Sweden | ⤷ Subscribe | PRODUCT NAME: VENETOCLAX; REG. NO/DATE: EU/1/16/1138 20161207 |
2435432 | 21/2017 | Austria | ⤷ Subscribe | PRODUCT NAME: VENETOCLAX; REGISTRATION NO/DATE: EU/1/16/1138 (MITTEILUNG) 20161207 |
2435432 | 132017000054735 | Italy | ⤷ Subscribe | PRODUCT NAME: VENETOCLAX(VENCLYXTO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1138, 20161207 |
2435432 | 300873 | Netherlands | ⤷ Subscribe | PRODUCT NAME: VENETOCLAX; REGISTRATION NO/DATE: EU/1/16/1138 20161207 |
2435432 | 122017000031 | Germany | ⤷ Subscribe | PRODUCT NAME: VENETOCLAX; REGISTRATION NO/DATE: EU/1/16/1138 20161205 |
2435432 | C201730016 | Spain | ⤷ Subscribe | PRODUCT NAME: VENETOCLAX; NATIONAL AUTHORISATION NUMBER: EU/1/16/1138; DATE OF AUTHORISATION: 20161205; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/16/1138; DATE OF FIRST AUTHORISATION IN EEA: 20161205 |
2435432 | 17C1018 | France | ⤷ Subscribe | PRODUCT NAME: VENETOCLAX; REGISTRATION NO/DATE: EU/1/16/1138 20161207 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Venetoclax Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.